DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer

Not Applicable

Withdrawn

Conditions: Lung Cancer

Interventions: Drug: Indocyanine green (ICG)
Device: FluoSCOPE

First Posted Date: 2015-04-22

Last Posted Date: 2018-05-16

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02423148

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Phase 1

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Pazopanib
Drug: Sorafenib
Drug: Radium-223

First Posted Date: 2015-04-02

Last Posted Date: 2020-03-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT02406521

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Ixazomib
Drug: Dexamethasone
Drug: Rituximab

First Posted Date: 2015-03-27

Last Posted Date: 2020-09-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 26

Registration Number: NCT02400437

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study

Completed

Conditions: Myelodysplastic Syndromes (MDS)

First Posted Date: 2015-03-17

Last Posted Date: 2023-04-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 290

Registration Number: NCT02390414

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Elotuzumab
Drug: Bortezomib
Drug: Dexamethasone
Procedure: Stem Cell Mobilization

First Posted Date: 2015-03-02

Last Posted Date: 2024-09-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT02375555

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 4 locations

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Phase 2

Completed

Conditions: Diffuse Large B Cell Lymphoma
Hodgkin Lymphoma
Peripheral T-Cell Lymphoma

Interventions: Drug: Pembrolizumab

First Posted Date: 2015-02-13

Last Posted Date: 2023-07-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 82

Registration Number: NCT02362997

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 3 locations

Patient-Centered Care for the Older Adult With Hematologic Malignancy

Not Applicable

Completed

Conditions: Hematologic Malignancy

Interventions: Other: Baseline Geriatric Screening/Assessment
Other: Geriatrician Co-Management

First Posted Date: 2015-02-10

Last Posted Date: 2022-07-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 160

Registration Number: NCT02359838

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture

Completed

Conditions: Childhood Cancer Survivors
Bone Mineral Density

Interventions: Other: Dual energy x-ray absorptiometry (DXA)
Other: Peripheral quantitative computed tomography (pQCT)

First Posted Date: 2015-02-04

Last Posted Date: 2024-08-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT02355340

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

Phase 2

Active, not recruiting

Conditions: Chronic Graft-versus-host-disease

Interventions: Procedure: Extracorporeal Photopheresis (ECP)
Drug: Interleukin-2

First Posted Date: 2015-01-19

Last Posted Date: 2025-02-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT02340676

Locations: 🇺🇸
Dana-Farber Cancer Insitute, Boston, Massachusetts, United States

Pembrolizumab +/- Bevacizumab for Recurrent GBM

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Drug: Pembrolizumab
Drug: Bevacizumab

First Posted Date: 2015-01-13

Last Posted Date: 2020-12-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 80

Registration Number: NCT02337491

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy